Windlas Biotech Limited — Updates, 12-08-2025: Press Release

Windlas Biotech reports strong Q1FY26 results, marking its 10th consecutive quarter of record revenue. Revenue grew 20% YoY to Rs. 210 Cr, with PAT up 31% to Rs. 17.7 Cr. All three segments performed well: CDMO revenue up 18%, Trade Generics 25%, and Exports 45%. The company is strengthening operations with Plant 6 upgrade and enhancing its injectable facility. Management remains optimistic on the pharma sector, focusing on efficiency and capacity expansion for sustainable growth.